CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.

Ther Adv Med Oncol. 2018;10:1758835918818346

Authors: Matutino A, Amaro C, Verma S

Abstract
The development of cyclin-dependent kinase (CDK) 4/6 inhibitors has been more prominent in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancers, with a significant improvement in progression-free survival (PFS) in first and later lines of metastatic breast cancer (MBC) therapy. Preclinical evidence suggests that there is activity of CDK4/6 inhibitors in nonluminal cell lines. Here, we present a review of the current preclinical and clinical data on the use of CDK inhibitors in HER2-positive and triple-negative breast cancer (TNBC).

PMID: 30619511 [PubMed]

from A via a.sfakia on Inoreader http://bit.ly/2Ccpi7n